Dark

Check out our Dark Pool Levels

TNGX
Tango Therapeutics, Inc.
stock NASDAQ

At Close

Jun 20, 2025 3:59:52 PM EDT

5.15USD+7.292%(+0.35)4,982,838

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jun 20, 2025 8:07:30 AM EDT

4.80USD0.000%(0.00)500

After-hours

Jun 20, 2025 4:36:30 PM EDT

5.15USD0.000%(0.00)21,652

OverviewOptionsHistoricalExchangesShortsNews

Jan 24, 2022

07:28AM EST Tango Therapeutics Says FDA Clears TNG908 IND And Sees First-in-human Clinical Trial To Start In H1 RTTNews

07:06AM EST Tango Therapeutics Announces Clearance Of TNG908 IND By FDA And Recent Pipeline Progress Updates Benzinga

07:00AM EST - TNG908 IND cleared by FDA, Phase 1/2 trial expected to start in 1H 2022 GlobeNewswire Inc

Nov 11, 2021

07:00AM EST Tango Therapeutics to Participate in the Jefferies London GlobeNewswire Inc

Nov 9, 2021

11:33AM EST Tango Therapeutics Q3 EPS $(0.28) Up From $(0.76) YoY Benzinga

07:00AM EST - Strong cash position of $504 million supports advancing discovery and clinical pipeline into second half of 2024- GlobeNewswire Inc

Nov 1, 2021

07:00AM EDT Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced two recent senior management appointments: Marc Rudoltz, M.D., as Chief Medical Officer, and Doug Barry, J.D., as General Counsel. GlobeNewswire Inc

Sep 30, 2021

04:32PM EDT Tango Therapeutics Announces Presentation Of Preclinical Data On Lead Program And Discovery Platform In Five Abstracts Accepted At AACR-NCI-EORTC 2021 Benzinga

Sep 20, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2021 Benzinga

07:16AM EDT SVB Leerink Initiates Coverage On Tango Therapeutics with Outperform Rating, Announces Price Target of $25 Benzinga

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 10, 2021

08:00AM EDT The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test Benzinga

Sep 8, 2021

07:32AM EDT The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod Benzinga

Sep 7, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021 Benzinga

08:25AM EDT Wedbush Initiates Coverage On Tango Therapeutics with Outperform Rating, Announces Price Target of $20 Benzinga

06:05AM EDT Guggenheim Initiates Coverage On Tango Therapeutics with Buy Rating, Announces Price Target of $16 Benzinga

05:01AM EDT Goldman Sachs Initiates Coverage On Tango Therapeutics with Buy Rating, Announces Price Target of $17 Benzinga

Share